---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040151"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:39:34.625705+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q2 net loss $17.4M; FDA aligns on Phase 2 dose for PC14586

## Summary
- Cash, equivalents & marketable securities $218.8M as of June 30, 2023, down from $277.4M a year ago.
- Net loss for six months ended June 30, 2023 was $36.6M vs. $35.7M in same period 2022.
- R&D expenses rose to $28.9M for six months, driven by headcount and clinical costs for PC14586.
- FDA alignment obtained on recommended Phase 2 dose and key elements of registrational trial; Phase 1 data update expected 2H 2023.
- Appointed Dr. Masha Poyurovsky as Vice President of Biology; ongoing combination arm with KEYTRUDA.

## SEC filing metadata
- accession: 0000950170-23-040151
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/0000950170-23-040151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/pmvp-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040151
- JSON: https://secwatch.observer/filing/0000950170-23-040151.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040151.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported Six months ended June 30, 2023 results: net income -$36.6 million.
  - Period: Six months ended June 30, 2023
  - Net income: -$36.6 million
  - Result: reported results
  source text: Net loss for the six months ended June 30, 2023, was $36.6 million compared to $35.7 million for the six months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/0000950170-23-040151-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.